Evidence-Based Management from Pre-Anesthetic Evaluation to Recovery
Chronic kidney disease (CKD) is among the most common comorbidities encountered in small animal veterinary practice, especially in older pets. The good news is that kidney disease does not automatically mean anesthesia is unsafe. Veterinary teams routinely manage anesthesia in pets with kidney disease, but these cases require thoughtful planning and vigilant monitoring to reduce risk. Renal disease can impact multiple organ systems, and anesthetic planning differs slightly from that of an otherwise healthy patient.
Pre-Anesthetic Information Mining: Gathering the Pieces of the Puzzle
Effective anesthetic planning for patients with kidney disease starts with a thorough history, as successful anesthesia in pets with kidney disease depends heavily on identifying stability, progression, and concurrent pathology early in the process. Trends in hydration, appetite, urination, and medication use provide important clues, as do physical examination findings. Veterinary clinicians aim to determine stability, progression, and concurrent pathology.
The rationale for such diligence is rooted in science! Acute kidney injury (AKI) remains a serious concern across species, with outcomes influenced by concurrent disease, anemia, nutritional status, and procedural factors. A recently published study emphasizes that:
“Concomitant comorbidities, age, size, type, timing, the urgency of surgery, improper fluid management, anemia, hyperglycemia, malnutrition, the use of blood and blood products, contrast dyes, diuretics, and exposure to nephrotoxins are the main factors in the development of AKI”1
Ensuring that the veterinary team has as much information as possible about the patient helps confirm that all risks are being considered when developing an anesthetic plan. For owners, this explains why veterinary teams ask so many questions before and during your consultation and emphasizes the importance of pre-anesthetic diagnostics such as blood work and/or imaging.
Pre-Anesthetic Diagnostics: Clinical Decision Tools
Blood work provides objective insight into kidney function, electrolyte balance, and overall systemic health, all of which directly influence risk assessment and decision-making surrounding anesthesia in pets with kidney disease. Certain abnormalities may prompt additional diagnostic testing, such as urinalysis or blood pressure measurement. Blood work, therefore, functions as a decision-making tool rather than a formality. Results may influence fluid therapy decisions, drug selection, monitoring intensity, and sometimes whether anesthesia should proceed at all.
Among all laboratory values reviewed before anesthesia, serum creatinine and blood urea nitrogen (BUN) are central to evaluating kidney health and anesthetic risk. Both reflect nitrogenous waste accumulation when filtration capacity declines, but they represent different physiological processes and are ideally interpreted together rather than in isolation.
Creatinine and Glomerular Filtration
Creatinine is widely used as a practical surrogate marker of glomerular filtration rate (GFR) because its concentration rises as functional nephron mass decreases. However, serum creatinine may remain within reference intervals until substantial kidney tissue is lost. Variation in muscle mass or diet can also influence values.
The severity of creatinine elevation typically corresponds with disease progression. Mild increases may reflect early disease, whereas moderate to marked increases in nitrogenous waste products signal more advanced dysfunction. This gradation matters when developing an anesthetic plan.
Blood Urea Nitrogen (BUN)
BUN provides complementary information. Urea is generated through protein metabolism and eliminated by renal excretion. Elevation can indicate impaired filtration, but BUN is more sensitive to hydration status, gastrointestinal factors, and protein intake than creatinine.
Disproportionate elevation of BUN relative to creatinine may reflect pre-renal influences such as dehydration, while concurrent increases in both values are more consistent with true renal dysfunction
SDMA and Early Detection
Symmetric dimethylarginine (SDMA) has become an additional diagnostic tool for evaluating kidney health. Abnormal SDMA concentrations often reflect reduced filtration earlier in the disease process than creatinine and are incorporated into International Renal Interest Society (IRIS) staging frameworks.
When available, SDMA can help identify decreased renal function in patients whose creatinine remains within reference intervals, allowing for earlier disease recognition and risk assessment.
Electrolytes and Acid–Base Balance
Electrolyte concentrations provide insight into the systemic impact of kidney disease. Abnormalities in potassium (K+) can affect cardiac conduction and anesthetic safety. Mild changes may require monitoring, while significant deviations often warrant medical management prior to anesthesia.
Phosphorus (PHOS) may increase with reduced renal excretion and reflect disease progression. Acid–base disturbances, particularly metabolic acidosis in advanced disease, can influence ventilation strategies and drug distribution during anesthesia.
Complete Blood Count and Protein Status
Complete blood count (CBC) findings offer additional information regarding disease progression. Reduced red blood cell mass (PCV/HCT) is common in chronic kidney disease due to decreased erythropoietin production. Mild anemia often has minimal anesthetic impact, whereas more substantial anemia may affect oxygen delivery, fluid rate decisions, and recovery expectations.
Serum protein concentrations help guide fluid therapy planning because altered oncotic pressure influences intravascular volume stability and blood pressure management under anesthesia.
Blood Pressure Assessment
Isolated laboratory abnormalities rarely function as absolute “safe versus unsafe” indicators. Clinicians evaluate the entire clinical picture when making recommendations.
Advanced kidney disease is frequently associated with systemic hypertension. Ideally, blood pressure measurements are obtained during routine visits rather than only on the morning of anesthesia. However, the “white coat effect” can make baseline assessment challenging in veterinary patients.
Determining Severity: IRIS Staging
To standardize assessment and communication, chronic kidney disease in dogs and cats is commonly categorized using the IRIS (International Renal Interest Society) staging system. Staging is based primarily on renal filtration markers (creatinine, BUN and SDMA) measured in stable, hydrated patients and is refined using additional parameters, including blood pressure status. Early stages represent reduced renal reserve with minimal clinical impact, while later stages indicate progressively diminished function and greater systemic consequences.
For anesthetic planning, staging provides critical information for risk discussion between veterinarians and pet owners. Patients with higher-stage disease are more likely to need intensive perioperative support and monitoring.
Blood work parameters that help determine IRIS staging are as follows:
- Stage 1
- Dogs with creatinine less than 1.4 mg/dL
- Cats with creatinine less than 1.6 mg/dL
- Dogs and cats with SDMA less than 18 μg/dL
- Stage 2
- Dogs with creatinine between 1.4-2.8 mg/dL
- Cats with creatinine between 1.6-2.8 mg/dL
- Dogs with SDMA between 18-35 μg/dL
- Cats with SDMA between 18-25 μg/dL
- Stage 3
- Dogs and cats with creatinine between 2.9-5.0 mg/Dl
- Dogs with SDMA between 36-54 μg/dL
- Cats with SDMA between 26-38 μg/dL
- Stage 4
- Dogs and cats with creatinine greater than 5.0 mg/dL
- Dogs with SDMA greater than 54 μg/dL
- Cats with SDMA greater than 38 μg/dL
Protocol Design: Anesthesiologist Decision-Making
The presence of kidney disease influences protocol decisions made about drugs chosen, dosing, and technique. Because altered clearance can prolong drug effects, clinicians often favor titratable, balanced approaches that avoid excessive cardiovascular depression.
When developing a plan, an opioid-based premedication and cautious induction strategy that emphasizes using the lowest effective dose is prioritized.
Certain drugs may be avoided, or their doses significantly reduced. One example of a drug class that’s contraindicated in patients with advanced kidney disease is the Non-Steroidal Anti-Inflammatory Drug (NSAID) class. The exclusion of this drug class presents significant challenges that the veterinary team must navigate. Alternative strategies to manage analgesia, such as a long-acting opioid or locoregional analgesic techniques, may be used to treat and prevent pain.
Intraoperative Management: Protecting Renal Perfusion
During anesthesia, maintaining adequate renal blood flow becomes the central objective, as hemodynamic stability is fundamental to safe anesthesia in pets with kidney disease. Clinically, this means that maintaining blood pressure in a normal range is one of the most prominent goals. Hypotension is a significant concern for any patient undergoing anesthesia, but a patient with a history of kidney dysfunction is at a higher risk of further damaging the remaining functional nephrons.
Modern perioperative review continues to highlight the systemic consequences of kidney injury, linking it to increased mortality, resource utilization, and hospitalization duration:
“Perioperative AKI… is associated with increased morbidity, mortality… and prolonged hospital stays.”
As a result, intraoperative management prioritizes cardiovascular stability, appropriate fluid support, thermal regulation, and efficiency to reduce time under anesthesia. Monitoring modalities such as blood pressure monitoring (with the most critical cases warranting the placement of an arterial catheter to monitor blood pressure in real-time) and oxygenation evaluation (with either a non-invasive modality such as a SpO2 monitor or an arterial blood gas evaluation) are essential.
Post-Operative Monitoring and Recovery
Good management does not end at extubation. Patients with kidney disease benefit from continued monitoring of perfusion, hydration, and urine production, as well as follow-up laboratory evaluation when indicated. Fluid therapy and analgesic plans may be adjusted based on recovery trajectory.
For pet owners, discharge instructions often include monitoring appetite, activity, and elimination patterns as early behavioral changes may signal complications.
Kidney disease introduces complexity into anesthetic management, but such a diagnosis does not take anesthesia off the table or warrant skipping essential preventative care, such as a dental cleaning. Evidence across veterinary and human literature consistently recommends thorough preparation as a foundational element of risk reduction. You’ll notice this blog post contains much more information about the management of a patient with this disease process before an intravenous catheter is ever placed. That’s intentional!
Careful information gathering, laboratory evaluation, stabilization, individualized protocol development, and attentive perioperative monitoring collectively ensure that all measures are being taken to create the safest anesthetic event possible while also ensuring that the owner is informed about the risks associated with anesthesia in pets with kidney disease. By having a board-certified veterinary anesthesiologist on your pet’s or patient’s care team, you are tapping into that specialist’s knowledge and years of dedicated training to provide a high standard of care.
Photo by Tran Mau Tri Tam ✪ on Unsplash used with permission under the Creative Commons license for commercial use 02/23/3036